IGC Pharma Inc
IGC Pharma Inc (IGC) is a small-cap pharmaceutical company with a market capitalisation of approximately $35.9 million. As a company operating in the pharmaceutical sector, it is likely focused on research, development and commercialisation of drug candidates or related technologies; investors should consult company filings for precise details on its pipeline and strategy. Micro-cap stocks such as IGC can offer meaningful upside if clinical or commercial milestones are met, but they also carry heightened risks: limited liquidity, wide price swings, and potential need for additional funding that can dilute shareholders. Typical investor considerations include the stage of development, cash runway, partnerships, regulatory progress and management track record. This overview is educational only and not personal financial advice; IGC may suit risk-tolerant investors with a long-term horizon, but it may be inappropriate for those needing capital preservation or low volatility.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying IGC Pharma's stock, expecting its value to rise significantly.
Financial Health
IGC Pharma is generating modest revenue and some cash flow, but its overall financial position is average.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IGC
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Microcap market dynamics
A market cap near $36m can provide meaningful upside if milestones are hit, though expect higher volatility and reduced liquidity compared with larger stocks.
R&D catalysts and trials
Clinical or regulatory progress tends to be a primary value driver for pharma firms; outcomes are often binary and can move the share price sharply.
Funding and partnerships
Smaller pharmaceutical companies commonly rely on partnerships or capital raises to advance programmes, which can dilute holders but also de‑risk development if done strategically.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
